Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes.
AD Rodrigues - Biochemical pharmacology, 1999 - europepmc.org
With the increased availability of human liver tissue, recombinant (cDNA-expressed) cytochrome
P450 proteins (rCYPs), and knowledge of the human CYP pool (eg immunoquantitated …
P450 proteins (rCYPs), and knowledge of the human CYP pool (eg immunoquantitated …
Pharmacokinetic drug interactions involving 17α-ethinylestradiol: a new look at an old drug
…, P Balimane, Z Yang, M Sinz, AD Rodrigues - Clinical …, 2007 - Springer
17α-Ethinylestradiol (EE) is widely used as the estrogenic component of oral contraceptives
(OC). In vitro and in vivo metabolism studies indicate that EE is extensively metabolised, …
(OC). In vitro and in vivo metabolism studies indicate that EE is extensively metabolised, …
Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?
AD Rodrigues - Drug Metabolism and Disposition, 2005 - ASPET
The market withdrawals of rofecoxib (Vioxx) and valdecoxib (Bextra) have focused considerable
attention on the side effect profiles of cyclooxygenase (COX) inhibitors. As a result, …
attention on the side effect profiles of cyclooxygenase (COX) inhibitors. As a result, …
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir
…, KC Marsh, G Kumar, AD Rodrigues… - Antimicrobial agents …, 1997 - Am Soc Microbiol
Coadministration with the human immunodeficiency virus (HIV) protease inhibitor ritonavir
was investigated as a method for enhancing the levels of other peptidomimetic HIV protease …
was investigated as a method for enhancing the levels of other peptidomimetic HIV protease …
Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes.
GN Kumar, AD Rodrigues, AM Buko… - Journal of Pharmacology …, 1996 - ASPET
The HIV-1 protease inhibitor ritonavir (ABT-538) undergoes cytochrome P450-mediated
biotransformation in human liver microsomes to three major metabolites, Ml, M2 and M11, with …
biotransformation in human liver microsomes to three major metabolites, Ml, M2 and M11, with …
Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions
BW Ogilvie, D Zhang, W Li, AD Rodrigues… - Drug Metabolism and …, 2006 - ASPET
Gemfibrozil more potently inhibits CYP2C9 than CYP2C8 in vitro, and yet the opposite
inhibitory potency is observed in the clinic. To investigate this apparent paradox, we evaluated …
inhibitory potency is observed in the clinic. To investigate this apparent paradox, we evaluated …
Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19
…, A Wagner, A Chimalakonda, AD Rodrigues - Drug Metabolism and …, 2012 - ASPET
Six proton pump inhibitors (PPIs), omeprazole, lansoprazole, esomeprazole, dexlansoprazole,
pantoprazole, and rabeprazole, were shown to be weak inhibitors of cytochromes P450 (…
pantoprazole, and rabeprazole, were shown to be weak inhibitors of cytochromes P450 (…
Structural characterization of indium oxide nanostructures: a Raman analysis
OM Berengue, AD Rodrigues… - Journal of Physics D …, 2010 - iopscience.iop.org
In this work we report on structural and Raman spectroscopy measurements of pure and Sn-doped
In 2 O 3 nanowires. Both samples were found to be cubic and high quality single …
In 2 O 3 nanowires. Both samples were found to be cubic and high quality single …
Substrate inhibition kinetics for cytochrome P450-catalyzed reactions
…, P Lu, C Tang, Q Mei, G Sandig, AD Rodrigues… - Drug Metabolism and …, 2001 - ASPET
Most cytochrome P450 (P450 or CYP)-catalyzed reactions are adequately described by
classical Michaelis-Menten kinetic parameters (eg, K m andV max ), which are usually …
classical Michaelis-Menten kinetic parameters (eg, K m andV max ), which are usually …
Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor
…, M Shou, Q Mei, TH Rushmore, AD Rodrigues - Journal of Pharmacology …, 2000 - ASPET
In vitro studies were conducted to identify the cytochromes P450 (CYP) involved in the
oxidative metabolism of celecoxib. The hydroxylation of celecoxib conformed to monophasic …
oxidative metabolism of celecoxib. The hydroxylation of celecoxib conformed to monophasic …